Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.
“We are now ending the era of misbelief and mistrust and moving onto the scientific proven therapies for the treatment of migraine.”
In the last 5—10 years, migraine has changed with the introduction of new mechanism based-treatments. After the FDA approved erenumab in May (Aimovig, Amgen/Novartis) and the recent approval of fremanezumab, the second approved member of this new class of medications, hope surrounding the remaining calcitonin gene-related peptide (CGRP) inhibitors has soared.
The migraine future is bright, as we have new drugs being developed that are mechanism-based, Stephen Silberstein, MD, Professor of Neurology, Thomas Jefferson University, and Director of the Jefferson Headache Center, told NeurologyLive in an interview. We now have an understanding of the mechanism of migraine and are working to target the mechanism themselves.
Silberstein began his career in headache utilizing the first triptan, and now, has witnessed something just as revolutionary with the new CGRP drugs. The industry is now ending the era of misbelief and moving onto scientific proven therapies for the treatment of migraine.
Related Content:Jefferson Health Vickie and Jack Farber Institute for Neuroscience | Clinical | News | Headache and Migraine | SAP Partners